Track topics on Twitter Track topics that are important to you
This is a Phase 2, multicenter, open-label, single-arm study of rivoceranib to evaluate its efficacy and safety in adult subjects with metastatic ACC of all anatomic sites of origin.
Not yet recruiting
LSK BioPartners Inc.
Published on BioPortfolio: 2019-10-15T11:11:26-0400
Comparing the efficacy of rivoceranib and trifluridine/tipiracil administered individually as monotherapies, as well as a rivocernib plus trifluridine/tipiracil combination therapy in the ...
This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (...